Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting

Apellis announced 5 abstracts that will be orally presented at the American

(Image credit: ©Kit Leong/AdobeStock)

Society of Retina Specialists (ASRS) Annual Scientific Meeting held July 30 through August 2 in Long Beach, California.

Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension. OAKS and DERBY are multicenter, phase 3, randomized, double-masked trials evaluating pegcetacoplan injection (SYFOVRE) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Caroline Baumal, MD, chief medical officer of Apellis, commented on the upcoming presentations in a press release from the company, saying, “Retina specialists continue to be excited about SYFOVRE—the most chosen treatment for GA—as demonstrated by the five oral presentations at this prestigious meeting. As leaders in GA, we are proud to present data that highlights SYFOVRE’s unique ability to slow GA progression in as few as six doses per year, offering hope to patients living with this progressive and irreversible disease.”

Presentations announced by the company include:

• Baseline Characteristics Associated with Geographic Atrophy Progression in the OAKS and DERBY Trials
  • Presented by Srinivas R. Sadda, MD, at the Dry AMD Symposium 1 on Thursday, July 31, 2:16-2:19 pm PT
    
• Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results from OAKS, DERBY, and GALE Open-Label Extension
  • Presented by Roger A Goldberg, MD, MBA, at the Dry AMD Symposium 1 on Thursday, July 31, 2:19-2:22 pm PT
    
• Clinical Utility of the Fellow Eye in Patients with Bilateral GA due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
  • Presented by Diana V. Do, MD, FASRS, at the Dry AMD Symposium 1 on Thursday, July 31, 2:22-2:25 pm PT
    
• A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment of Geographic Atrophy and Neovascular AMD
  • Presented by Nimesh A. Patel, MD, FASRS, at the Dry AMD Symposium 1 on Thursday, July 31, 2:38-2:41 pm PT
    
• Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights from the Phase 3 OAKS and DERBY Trials
  • Presented by Paul Hahn, MD, PhD, FASRS, at the Dry AMD Symposium 2 on Thursday, July 31, 3:14-3:17 pm PT

Reference:

1. Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. Published July 15, 2025. Accessed July 15, 2025. https://investors.apellis.com/news-releases/news-release-details/apellis-announces-five-abstracts-accepted-oral-presentation-0